Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Keytruda is currently indicated in a variety of cancers, including classical Hodgkin lymphoma, primary mediastinal large ...

BioNTech adds bispecific candidate, mRNA delivery startup as cancer work takes center stage The opportunity is enormous: ...

If you're patient, these businesses have a lot of promising projects in the works. Much to the chagrin of investors ... Merck ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda. The PD-1 checkpoint inhibitor cancer treatment is fast ...

Drugs like pembrolizumab (Keytruda) can be used in combination with chemotherapy ... Additionally, radiation therapy and surgery may be used to alleviate symptoms. Patients must work closely with ...

CEL-SCI Corporation today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company's approach to patient selection using low PD-L1 tumor expression in ...

AN orange zombie fungus that sprouts from the backs of caterpillars could be used to fight cancer, new research suggests. Scientists have found the fungus, called Cordyceps, works by stopping cell ...

Or how would that work? John Johnson-- Chief Financial Officer Yes ... And we've also seen an extension in longer duration ...